The chairman of Sofinnova Partners says “now is a prime time” to be investing in European biotech start-ups, as the region offers cutting edge science and technology, less frothy asset price tags, and a growing role to bridge commercial opportunities in the US and in China.
Antoine Papiernik made the comments to Scrip when outlining the thinking behind Sofinnova’s latest funding round, completed October 18, which...